Trial Profile
68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary)
- Indications Bladder cancer; Breast cancer; Prostate cancer
- Focus Adverse reactions; Diagnostic use; First in man
- Acronyms uPAR-PET
- 21 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2015 New trial record